Palbociclib plus endocrine therapy significantly enhances overall survival of<scp>HR</scp>+/<scp>HER2</scp>− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study-Reference-Cited by-同舟云学术

Palbociclib plus endocrine therapy significantly enhances overall survival ofHR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study

Published:2022-03-03 Issue:12 Volume:150 Page:2025-2037
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Ha Min Jin¹²^ORCID,Singareeka Raghavendra Akshara³^ORCID,Kettner Nicole M.⁴,Qiao Wei¹,Damodaran Senthil³,Layman Rachel M.³,Hunt Kelly K.⁵,Shen Yu¹,Tripathy Debu³,Keyomarsi Khandan⁴^ORCID

Affiliation:

1. Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas USA

2. Department of Biostatistics Graduate School of Public Health, Yonsei University Seoul Korea

3. Department of Breast Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

4. Department of Experimental Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

5. Department of Breast Surgical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

Funder

Cancer Prevention and Research Institute of Texas

National Cancer Institute

U.S. Department of Defense

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33959

Reference59 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

3. Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015)

4. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

5. Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patterns and outcomes in HR+/HER2- advanced/metastatic breast cancer patients in Brazil receiving palbociclib;Future Oncology;2024-09-05

2. Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer;Geburtshilfe und Frauenheilkunde;2024-09

3. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer;Breast Cancer Research and Treatment;2024-08-23

4. First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting;Breast Cancer Research and Treatment;2024-06-26

5. An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy;Biomedicines;2024-02-22